Shockwave Medical Stock Forecast

The growth was primarily driven by the launch of. On average, they anticipate shockwave medical's stock price to reach $238.33 in the next year.

Ryipqk-jtcdjam

There are a lot of things to like about shockwave medical stock, particularly shares’ outrageously strong performance since the ipo in march.

Shockwave medical stock forecast. Swav stock forecast our latest prediction for shockwave medical inc's stock price was made on the aug. The company appears to have strong potential for both revenue growth and market disruption that it would be able to capitalize on. The company reported $0.05 earnings per share for the quarter, topping the zacks' consensus estimate of ($0.07) by $0.12.

Shockwave medical (swav) came out with quarterly earnings of $0.05 per share, beating the zacks consensus estimate of a loss of $0.07 per share. 1, 2019 at 2:22 p.m. It's clear from the latest estimates that shockwave medical's rate of growth is expected to accelerate meaningfully, with the forecast 195% annualised revenue growth to the end of 2021 noticeably.

The average price target represents a 29.81% upside from the last price of. This suggests a possible upside of 44.3% from the stock's current price. The company is forecast to post a net loss per share of us$0.60 next year compared to a net loss per share of us$1.99 last year.

Eps forecast (this quarter) $0.08: Find the latest shockwave medical, inc. Shockwave medical's share price could stay at $196.88 by nov 9, 2022.

Shockwave medical inc has risen higher in 2 of those 2 years over the subsequent 52 week period, corresponding to a historical accuracy of 100 % Their forecasts range from $200.00 to $272.00. 58 rows shockwave medical inc.

The average shockwave medical stock price prediction forecasts a potential downside of n/a from the current swav share price of $189.72. New target price is 13% above last closing price of us$217. The average price target is $238.33, with a high forecast of $272.00 and a low forecast of $200.00.

Is scoring comparatively higher than the scores of other players of the relevant industry. Shockwave medical started at buy with $39 stock price target at canaccord genuity. Stock is up 150% over the past year.

Shockwave medical (nasdaq:swav) last posted its quarterly earnings results on monday, november 8th. And 2527.753 usd for 2026 november 02, monday with technical analysis. The midpoint of that range.

For shockwave medical stock forecast 2022, 12 predictions are offered for each month of 2022 with average shockwave medical stock forecast of $217.81, a high forecast of $222.12, and a low forecast of $199.13. 21, 2020 when the stock price was at 59.06$. This compares to loss of $0.38 per share a year ago.

On average, wall street analysts predict that. Shockwave medical (swav) stock price prediction is 482.48274251026 usd. If you had invested in shockwave medical stock at $30.50 , your return over the last 2 years would have been 490.95% , for an annualized return of 143.09%.

Actively observing the price movement in the last trading, the stock closed the session at $241.83, falling within a range of $232.88 and $249.73. 7 equities research analysts have issued 1 year price targets for shockwave medical's stock. This price target is based on 7 analysts offering 12 month price targets for shockwave medical in the last 3 months.

Shockwave medical inc stock forecast over the next 52 weeks, shockwave medical inc has on average historically risen by 172.5 % based on the past 2 years of stock performance. Shockwave medical had a negative return on equity of 24.14% and a negative net margin of 40.60%. There are few to no technical positive signals at the moment.

Stock was originally listed at a price of $30.50 in mar 7, 2019. (swav) stock quote, history, news and other vital information to help you with your stock trading and investing. Annual revenue (last year) $67.8m:

Statistics highlight that shockwave medical inc. The shockwave medical stock forecast is 482.48274251026 usd for 2022 november 02, wednesday;

Shockwave Medical Stock Jumps On Q1 Revenue Growth Analyst Upgrades